Depleting syndecan-4+ T lymphocytes using toxin-bearing dendritic cell-associated heparan sulfate proteoglycan-dependent integrin ligand: A new opportunity for treating activated T cell-driven disease

Journal of Immunology

Volumn 184, Issue 7, 2010, Pages 3554-3561

  Akiyoshi, Hideo ^a,b   Chung, Jin Sung ^a   Tomihari, Mizuki ^a,c   Cruz Jr , Ponciano D ^a   Ariizumi, Kiyoshi ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Osaka Prefecture University   (Japan)

^c OBIHIRO UNIVERSITY OF AGRICULTURE AND VETERINARY MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FC RECEPTOR; GAMMA INTERFERON; HAPTEN; IMMUNOTOXIN; INTEGRIN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; LIGAND; MONOCLONAL ANTIBODY; PROTEOHEPARAN SULFATE; RECOMBINANT PROTEIN; SAPORIN; SYNDECAN 4; DC HIL PROTEIN, MOUSE; DC-HIL PROTEIN, MOUSE; HYBRID PROTEIN; IMMUNOGLOBULIN RECEPTOR; MEMBRANE PROTEIN; RIBOSOME INACTIVATING PROTEIN 1; SDC4 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTACT ALLERGY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HISTOLOGY; LYMPH NODE; LYMPH NODE CELL; LYMPHOCYTE DEPLETION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION; SKIN; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CONTACT DERMATITIS; DRUG EFFECT; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METABOLISM; METHODOLOGY;

ANIMALS; CYTOKINES; DERMATITIS, CONTACT; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOTHERAPY; IMMUNOTOXINS; LYMPH NODES; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; RECEPTORS, IMMUNOLOGIC; RECOMBINANT FUSION PROTEINS; RIBOSOME INACTIVATING PROTEINS, TYPE 1; SKIN; SYNDECAN-4; T-LYMPHOCYTES;

EID: 77951650745     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0903250     Document Type: Article

References (40)

1. Chambers, C. A., and J. P. Allison. 1997. Co-stimulation in T cell responses. Curr. Opin. Immunol. 9: 396-404.
2. Carreno, B. M., and M. Collins. 2002. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu. Rev. Immunol. 20: 29-53.
3. Carreno, B. M., F. Bennett, T. A. Chau, V. Ling, D. Luxenberg, J. Jussif, M. L. Baroja, and J. Madrenas. 2000. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression. J. Immunol. 165: 1352-1356.
4. Linsley, P. S., W. Brady, M. Urnes, L. S. Grosmaire, N. K. Damle, and J. A. Ledbetter. 1991. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174: 561-569.
5. Tivol, E. A., F. Borriello, A. N. Schweitzer, W. P. Lynch, J. A. Bluestone, and A. H. Sharpe. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3: 541-547.
6. Okazaki, T., and T. Honjo. 2007. PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 19: 813-824.
7. Sharpe, A. H., E. J. Wherry, R. Ahmed, and G. J. Freeman. 2007. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 8: 239-245.
8. Watanabe, N., M. Gavrieli, J. R. Sedy, J. Yang, F. Fallarino, S. K. Loftin, M. A. Hurchla, N. Zimmerman, J. Sim, X. Zang, et al. 2003. BTLA is a lymphocyte inhibitory receptor with similarities toCTLA-4 and PD-1.Nat. Immunol. 4: 670-679. (Pubitemid 36874444)
9. Carreno, B. M., and M. Collins. 2003. BTLA: a new inhibitory receptor with a B7-like ligand. Trends Immunol. 24: 524-527.
10. Han, P., O. D. Goularte, K. Rufner, B. Wilkinson, and J. Kaye. 2004. An inhibitory Ig superfamily protein expressed by lymphocytes and APCs is also an early marker of thymocyte positive selection. J. Immunol. 172: 5931-5939. (Pubitemid 38621192)
11. Zhu, C., A. C. Anderson, A. Schubart, H. Xiong, J. Imitola, S. J. Khoury, X. X. Zheng, T. B. Strom, and V. K. Kuchroo. 2005. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 6: 1245-1252.
12. Sánchez-Fueyo, A., J. Tian, D. Picarella, C. Domenig, X. X. Zheng, C. A. Sabatos, N. Manlongat, O. Bender, T. Kamradt, V. K. Kuchroo, et al. 2003. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat. Immunol. 4: 1093-1101.
13. Sabatos, C. A., S. Chakravarti, E. Cha, A. Schubart, A. Sánchez-Fueyo, X. X. Zheng, A. J. Coyle, T. B. Strom, G. J. Freeman, and V. K. Kuchroo. 2003. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat. Immunol. 4: 1102-1110.
14. Blank, C., and A. Mackensen. 2007. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol. Immunother. 56: 739-745.
15. Barber, D. L., E. J. Wherry, D. Masopust, B. Zhu, J. P. Allison, A. H. Sharpe, G. J. Freeman, and R. Ahmed. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687.
16. Shin, H., and E. J. Wherry. 2007. CD8 T cell dysfunction during chronic viral infection. Curr. Opin. Immunol. 19: 408-415.
17. Ahmadzadeh, M., L. A. Johnson, B. Heemskerk, J. R.Wunderlich, M. E. Dudley, D. E. White, and S. A. Rosenberg. 2009. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114: 1537-1544.
18. Shikano, S., M. Bonkobara, P. K. Zukas, and K. Ariizumi. 2001. Molecular cloning of a dendritic cell-associated transmembrane protein, DC-HIL, that promotes RGD-dependent adhesion of endothelial cells through recognition of heparan sulfate proteoglycans. J. Biol. Chem. 276: 8125-8134.
19. Chung, J. S., K. Sato, I. I. Dougherty, P. D. Cruz, Jr., and K. Ariizumi. 2007. DCHIL is a negative regulator of T lymphocyte activation. Blood 109: 4320-4327.
20. Chung, J. S., I. Dougherty, P. D. Cruz, Jr., and K. Ariizumi. 2007. Syndecan-4 mediates the coinhibitory function of DC-HIL on T cell activation. J. Immunol. 179: 5778-5784.
21. Chung, J. S., M. Bonkobara, M. Tomihari, P. D. Cruz, Jr., and K. Ariizumi. 2009. The DC-HIL/syndecan-4 pathway inhibits human allogeneic T-cell responses. Eur. J. Immunol. 39: 965-974.
22. Weterman, M. A., N. Ajubi, I. M. van Dinter, W. G. Degen, G. N. van Muijen, D. J. Ruitter, and H. P. Bloemers. 1995. nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts. Int. J. Cancer 60: 73-81.
23. Safadi, F. F., J. Xu, S. L. Smock, M. C. Rico, T. A. Owen, and S. N. Popoff. 2001. Cloning and characterization of osteoactivin, a novel cDNA expressed in osteoblasts. J. Cell Biochem. 84: 12-26. (Pubitemid 33101507)
24. Metz, R. L., P. S. Patel, M. Hameed, M. Bryan, and P. Rameshwar. 2007. Role of human HGFIN/nmb in breast cancer. Breast Cancer Res. 9: R58.
25. Cruz, P. D., Jr., and P. R. Bergstresser. 1988. The low-dose model of UVB-induced immunosuppression. Photodermatol. 5: 151-161.
26. Kadoshima-Yamaoka, K., M. Goto, M. Murakawa, R. Yoshioka, Y. Tanaka, H. Inoue, H. Murafuji, S. Kanki, Y. Hayashi, K. Nagahira, et al. 2009. ASB16165, a phosphodiesterase 7A inhibitor, reduces cutaneous TNF-alpha level and ameliorates skin edema in phorbol ester 12-O-tetradecanoylphorbol-13-acetate- induced skin inflammation model in mice. Eur. J. Pharmacol. 613: 163-166.
27. Cruz, P. D., Jr., J. Nixon-Fulton, R. E. Tigelaar, and P. R. Bergstresser. 1988. Local effects of UV radiation on immunization with contact sensitizers. I. Downregulation of contact hypersensitivity by application of TNCB to UV-irradiated skin. Photodermatol. 5: 126-132.
28. Flavell, D. J. 1998. Saporin immunotoxins. Curr. Top. Microbiol. Immunol. 234: 57-61.
29. Kelley, V. E., P. Bacha, O. Pankewycz, J. C. Nichols, J. R. Murphy, and T. B. Strom. 1988. Interleukin 2-diphtheria toxin fusion protein can abolish cell-mediated immunity in vivo. Proc. Natl. Acad. Sci. U.S.A. 85: 3980-3984.
30. Pastan, I., V. Chaudhary, and D. J. FitzGerald. 1992. Recombinant toxins as novel therapeutic agents. Annu. Rev. Biochem. 61: 331-354.
31. Phillips, S. M., M. K. Bhopale, C. S. Constantinescu, B. Ciric, B. Hilliard, E. Ventura, E. Lavi, and A. Rostami. 2007. Effect of DAB(389)IL-2 immunotoxin on the course of experimental autoimmune encephalomyelitis in Lewis rats. J. Neurol. Sci. 263: 59-69.
32. Foss, F. M. 2000. DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma. Clin. Lymphoma 1: 110-116, discussion 117.
33. Pistillo, M. P., P. L. Tazzari, J. H. Ellis, and G. B. Ferrara. 2000. Molecular characterization and applications of recombinant scFv antibodies to CD152 costimulatory molecule. Tissue Antigens 55: 229-238.
34. Tazzari, P. L., L. Polito, A. Bolognesi, M. P. Pistillo, P. Capanni, G. L. Palmisano, R. M. Lemoli, A. Curti, L. Biancone, G. Camussi, et al. 2001. Immunotoxins containing recombinant anti-CTLA-4 single-chain fragment variable antibodies and saporin: in vitro results and in vivo effects in an acute rejection model. J. Immunol. 167: 4222-4229.
35. Pistillo, M. P., P. L. Tazzari, G. L. Palmisano, I. Pierri, A. Bolognesi, F. Ferlito, P. Capanni, L. Polito, M. Ratta, S. Pileri, et al. 2003. CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. Blood 101: 202-209.
36. Freeman, G. J., A. J. Long, Y. Iwai, K. Bourque, T. Chernova, H. Nishimura, L. J. Fitz, N. Malenkovich, T. Okazaki, M. C. Byrne, et al. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192: 1027-1034.
37. Slimani, H., N. Charnaux, E. Mbemba, L. Saffar, R. Vassy, C. Vita, and L. Gattegno. 2003. Binding of the CC-chemokine RANTES to syndecan-1 and syndecan-4 expressed on HeLa cells. Glycobiology 13: 623-634. (Pubitemid 37220440)
38. Mora, J. R., and U. H. von Andrian. 2006. T-cell homing specificity and plasticity: new concepts and future challenges. Trends Immunol. 27: 235-243.
39. Marelli-Berg, F. M., L. Cannella, F. Dazzi, and V. Mirenda. 2008. The highway code of T cell trafficking. J. Pathol. 214: 179-189.
40. Huang, V., A. S. Lonsdorf, L. Fang, T. Kakinuma, V. C. Lee, E. Cha, H. Zhang, K. Nagao, M. Zaleska, W. L. Olszewski, and S. T. Hwang. 2008. Cutting edge: rapid accumulation of epidermal CCL27 in skin-draining lymph nodes following topical application of a contact sensitizer recruits CCR10-expressing T cells. J. Immunol. 180: 6462-6466.